ChromaDex (CDXC) and Its Peers Head to Head Analysis
ChromaDex (NASDAQ: CDXC) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare ChromaDex to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, analyst recommendations, valuation and dividends.
This table compares ChromaDex and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares ChromaDex and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ChromaDex||$26.81 million||-$2.92 million||-47.35|
|ChromaDex Competitors||$217.29 million||-$39.39 million||-55.55|
ChromaDex’s competitors have higher revenue, but lower earnings than ChromaDex. ChromaDex is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
6.8% of ChromaDex shares are held by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 11.6% of ChromaDex shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings for ChromaDex and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ChromaDex currently has a consensus target price of $7.00, indicating a potential upside of 5.58%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.39%. Given ChromaDex’s competitors higher probable upside, analysts clearly believe ChromaDex has less favorable growth aspects than its competitors.
Risk and Volatility
ChromaDex has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, ChromaDex’s competitors have a beta of 1.53, suggesting that their average share price is 53% more volatile than the S&P 500.
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Receive News & Ratings for ChromaDex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.